Papers/PMID:17054253
Strontium ranelate for preventing and treating postmenopausal osteoporosis.
The Cochrane database of systematic reviews2006The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
strontium(2+) — decreases vertebral fracture incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“A 37% reduction in vertebral fractures (RR 0.63, 95% CI 0.56, 0.71) and a 14% reduction in non-vertebral fractures (RR 0.86, 95% CI 0.75, 0.98) were demonstrated over three years with 2 g of strontium ranelate daily in a treatment population.”
Quoted verbatim from Strontium ranelate for preventing and treating postmenopausal osteoporosis.. - Study
- meta-analysis
- Dose
- strontium ranelate 2 g daily
- Population
- Postmenopausal women with osteoporosis (treatment population: prevalent vertebral fractures and/or lumbar spine BMD T score below -2.5 SD); pooled RCTs of strontium ranelate versus placebo; 2 g daily dose stratum, three years
Effect 0.63 risk ratio, 95% CI 0.56 to 0.71
Strontium ranelate for preventing and treating postmenopausal osteoporosis.2006PMID:17054253Permalink
strontium(2+) — decreases non-vertebral fracture incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“A 37% reduction in vertebral fractures (RR 0.63, 95% CI 0.56, 0.71) and a 14% reduction in non-vertebral fractures (RR 0.86, 95% CI 0.75, 0.98) were demonstrated over three years with 2 g of strontium ranelate daily in a treatment population.”
Quoted verbatim from Strontium ranelate for preventing and treating postmenopausal osteoporosis.. - Study
- meta-analysis
- Dose
- strontium ranelate 2 g daily
- Population
- Postmenopausal women with osteoporosis (treatment population: prevalent vertebral fractures and/or lumbar spine BMD T score below -2.5 SD); pooled RCTs of strontium ranelate versus placebo; 2 g daily dose stratum, three years
Effect 0.86 risk ratio, 95% CI 0.75 to 0.98
Strontium ranelate for preventing and treating postmenopausal osteoporosis.2006PMID:17054253Permalink